Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

Hepatology

Volumn 64, Issue 4, 2016, Pages 1136-1147

  Ganne Carrié, Nathalie ^a,b,c   Layese, Richard ^d   Bourcier, Valérie ^a   Cagnot, Carole ^e   Marcellin, Patrick ^f   Guyader, Dominique ^g   Pol, Stanislas ^h   Larrey, Dominique ⁱ   de Lédinghen, Victor ^j   Ouzan, Denis ^k   Zoulim, Fabien ^l   Roulot, Dominique ^b,m   Tran, Albert ⁿ   Bronowicki, Jean Pierre ^o   Zarski, Jean Pierre ^p   Riachi, Ghassan ^q   Calès, Paul ^r   Péron, Jean Marie ^s   Alric, Laurent ^t   Bourlière, Marc ^u   Mathurin, Philippe ^v   Blanc, Jean Frédéric ^w   Abergel, Armand ^x   Serfaty, Lawrence ^y   Mallat, Ariane ^d   Grangé, Jean Didier ^z   Attali, Pierre ^aa   Bacq, Yannick ^ab   Wartelle, Claire ^ac   Dao, Thông ^ad   Benhamou, Yves ^ae   Pilette, Christophe ^af   Silvain, Christine ^ag   Christidis, Christos ^ah   Capron, Dominique ^ai   Bernard Chabert, Brigitte ^aj   Zucman, David ^ak   Di Martino, Vincent ^al   Trinchet, Jean Claude ^a,b,c   Nahon, Pierre ^a,b,c   Roudot Thoraval, Françoise ^d   more..

^a HÔPITAL JEAN VERDIER   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c Université Paris 13   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e Unit for Basic and Clinical research on Viral Hepatitis   (France)

^f BEAUJON HOSPITAL   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

^j HAUT LÉVÊQUE HOSPITAL   (France)

^k INSTITUT ARNAULT TZANCK   (France)

^l CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^m AVICENNE HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF NICE   (France)

^o INSERM   (France)

^p GRENOBLE UNIVERSITY HOSPITAL   (France)

^q HÔPITAL CHARLES NICOLLE   (France)

^r ANGERS UNIVERSITY HOSPITAL   (France)

^s UNIVERSITÉ PAUL SABATIER   (France)

^t TOULOUSE UNIVERSITY HOSPITAL   (France)

^u HÔPITAL SAINT JOSEPH   (France)

^v LILLE UNIVERSITY HOSPITAL   (France)

^w HÔPITAL SAINT ANDRÉ   (France)

^x HÔTEL DIEU   (France)

^y HÔPITAL SAINT ANTOINE   (France)

^z HÔPITAL TENON   (France)

^aa HÔPITAL PAUL BROUSSE   (France)

^ab SERVICE DE DERMATOLOGIE   (France)

^ac Aix en Provence Hospital   (France)

^ad CHU CÔTE DE NACRE   (France)

^ae PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^af GENERAL HOSPITAL   (France)

^ag POITIERS UNIVERSITY HOSPITAL   (France)

^ah INSTITUT MUTUALISTE MONTSOURIS   (France)

^ai AMIENS UNIVERSITY HOSPITAL   (France)

^aj SERVICE DE DERMATOLOGIE   (France)

^ak FOCH HOSPITAL   (France)

^al UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON; RIBAVIRIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER DIAGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NOMOGRAM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTE COUNT; VIRUS REPLICATION; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS C; COMPLICATION; LIVER NEOPLASMS; PROSPECTIVE STUDY; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NOMOGRAMS; PROSPECTIVE STUDIES;

EID: 84988432440     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28702     Document Type: Article

References (31)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–1273.e1.
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35–S50.
3. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138–148.
4. Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, et al.; ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 2015;62:737–750.
5. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.
7. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131–136.
8. N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4:1062–1068.
9. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329–337.
10. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011;18:e516–e522.
11. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007;46:430–435.
12. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601–2608.
13. Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 2016;150:430–440.e1.
14. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059–1062.
15. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–2474.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
17. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579–587.
18. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of viral eradication in patients with HCV and cirrhosis differ with stage of portal hypertension. Gastroenterology 2016;15:130–139.e1.
19. Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol 2014;61:67–74.
20. Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996;23:1112–1118.
21. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520–527.
22. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568–574.
23. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80–88.
24. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660–1665.
25. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015;62:363–370.
26. Abu-Amara M, Cerocchi O, Malhi G, Sharma S, Yim C, Shah H, et al. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. Gut 2015 Apr 30. pii: gutjnl-2014-309099. doi: 10.1136/gutjnl-2014-309099. [Epub ahead of print]
27. Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481–2488.
28. Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, et al. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014;9:e94760.
29. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014;146:1249–1255.e1.
30. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98–107.
31. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584–2593.